Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Axitinib + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown Brivanib pancreatic cancer not applicable detail...
Unknown unknown Foretinib pancreatic cancer not applicable detail...
KRAS mutant GI-4000 pancreatic cancer predicted - sensitive detail...
TP53 loss MK-1775 + Gemcitabine pancreatic cancer sensitive detail...
Unknown unknown Nintedanib pancreatic cancer not applicable detail...
Unknown unknown Mithramycin pancreatic cancer not applicable detail...
CDKN2A loss PD0332991 + Gemcitabine pancreatic cancer decreased response detail...
CDKN2A loss GSK461364 + PD0332991 pancreatic cancer decreased response detail...
CDKN2A loss ON-01910 + PD0332991 pancreatic cancer decreased response detail...
CDKN2A loss HMN-214 + PD0332991 pancreatic cancer decreased response detail...
SMAD4 del Cisplatin pancreatic cancer sensitive detail...
SMAD4 del Irinotecan pancreatic cancer sensitive detail...
SMAD4 del Gemcitabine pancreatic cancer decreased response detail...
Unknown unknown Gemcitabine + GSK1120212 pancreatic cancer not applicable detail...
Unknown unknown Golvatinib pancreatic cancer not applicable detail...
KRAS G12X Binimetinib pancreatic cancer sensitive detail...
KRAS G12S Binimetinib pancreatic cancer sensitive detail...
KRAS G12C Cobimetinib pancreatic cancer sensitive detail...
KRAS G12X Cobimetinib pancreatic cancer sensitive detail...
Unknown unknown 2g8 pancreatic cancer sensitive detail...
PDGFRA act mut Vistusertib pancreatic cancer predicted - sensitive detail...
KRAS G12D UC-773587 pancreatic cancer resistant detail...
KRAS G12D UC-857993 pancreatic cancer resistant detail...
Unknown unknown PG545 + Gemcitabine pancreatic cancer not applicable detail...
KDR wild-type VEGFR2-169 + Gemcitabine pancreatic cancer sensitive detail...
Unknown unknown AS-252424 pancreatic cancer not applicable detail...
KRAS G12D Reolysin + Gemcitabine pancreatic cancer sensitive detail...
KRAS mutant Rigosertib + Gemcitabine pancreatic cancer no benefit detail...
KRAS G12C GDC-0623 pancreatic cancer sensitive detail...
KRAS mutant Pictilisib pancreatic cancer decreased response detail...
KRAS mutant Pictilisib + Selumetinib pancreatic cancer sensitive detail...
KRAS G12D Pictilisib + Selumetinib pancreatic cancer sensitive detail...
KRAS G12D Pictilisib pancreatic cancer decreased response detail...
KRAS mutant GDC-0980 + PD-0325901 pancreatic cancer sensitive detail...
KRAS G12C Gedatolisib pancreatic cancer sensitive detail...
Unknown unknown Conatumumab + Ganitumab pancreatic cancer not applicable detail...
Unknown unknown Chidamide pancreatic cancer not applicable detail...
KRAS G12D TP53 R175H Pimasertib + Gemcitabine pancreatic cancer sensitive detail...
Unknown unknown Pimasertib + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown PH11 pancreatic cancer not applicable detail...
KRAS G12X PHT-427 pancreatic cancer resistant detail...
Unknown unknown Metformin + PEXG pancreatic cancer no benefit detail...
BRAF V487_P492delinsA LY3009120 pancreatic cancer sensitive detail...
BRAF V487_P492delinsA Trametinib pancreatic cancer sensitive detail...
BRAF V487_P492delinsA Vemurafenib pancreatic cancer resistant detail...
BRAF V487_P492delinsA Dabrafenib pancreatic cancer resistant detail...
SMAD4 dec exp N/A pancreatic cancer not applicable detail...
SMAD4 inact mut Irinotecan pancreatic cancer sensitive detail...
Unknown unknown AIM-100 pancreatic cancer not applicable detail...
Unknown unknown Napabucasin pancreatic cancer not applicable detail...
STK11 D194E STK11 loss Everolimus pancreatic cancer sensitive detail...
Unknown unknown Metformin pancreatic cancer no benefit detail...
KDR positive TAS-115 pancreatic cancer sensitive detail...
SF3B1 K700E Spliceostatin A pancreatic cancer sensitive detail...
Unknown unknown SRT3025 pancreatic cancer not applicable detail...
Unknown unknown ABTL0812 pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + nab-paclitaxel + Necuparanib pancreatic cancer not applicable detail...
BRCA2 mutant Rucaparib pancreatic cancer predicted - sensitive detail...
BRCA1 mutant Rucaparib pancreatic cancer predicted - sensitive detail...
Unknown unknown Demcizumab + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown Vantictumab + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Uproleselan pancreatic cancer not applicable detail...
Unknown unknown Erlotinib + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown MitoMet-10 pancreatic cancer not applicable detail...
FGFR1 dec exp KRAS mut Trametinib pancreatic cancer sensitive detail...
KRAS mutant Ponatinib + Trametinib pancreatic cancer sensitive detail...
KRAS G12D Ponatinib + Trametinib pancreatic cancer sensitive detail...
Unknown unknown CBP501 + Cisplatin pancreatic cancer not applicable detail...
Unknown unknown Bleomycin + CBP501 pancreatic cancer not applicable detail...
BRAF wild-type KRAS G12D GDC0879 pancreatic cancer resistant detail...
KRAS G12D EZH2 pos DZNep + Selumetinib pancreatic cancer no benefit detail...
KRAS G12C EZH2 pos DZNep + Selumetinib pancreatic cancer sensitive detail...
KRAS G12D EZH2 pos DZNep + MK2206 pancreatic cancer sensitive detail...
KRAS G12C EZH2 pos DZNep + MK2206 pancreatic cancer sensitive detail...
KRAS G12D rigosertib pancreatic cancer sensitive detail...
ERBB2 positive DS-8201a pancreatic cancer sensitive detail...
KRAS G12D Aphanin pancreatic cancer predicted - sensitive detail...
KRAS wild-type Aphanin pancreatic cancer decreased response detail...
Unknown unknown CG200745 pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Tacedinaline pancreatic cancer no benefit detail...
KRAS mutant PF3644022 + PF-477736 pancreatic cancer predicted - sensitive detail...
ROS1 positive Entrectinib pancreatic cancer predicted - sensitive detail...
Unknown unknown Vandetanib + Gemcitabine pancreatic cancer no benefit detail...
Unknown unknown Gemcitabine + Refametinib pancreatic cancer not applicable detail...
KRAS wild-type Gemcitabine + Refametinib pancreatic cancer predicted - sensitive detail...
Unknown unknown ABC294640 + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown MVT-1075 pancreatic cancer not applicable detail...
Unknown unknown MVT-5873 pancreatic cancer not applicable detail...
Unknown unknown MVT-5873 + Gemcitabine + nab-paclitaxel pancreatic cancer not applicable detail...
Unknown unknown Pegilodecakin pancreatic cancer not applicable detail...
Unknown unknown Capecitabine + Pegilodecakin pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + LY2603618 pancreatic cancer no benefit detail...
Unknown unknown BGB-A317 + Pamiparib pancreatic cancer not applicable detail...
Unknown unknown BRD4770 pancreatic cancer not applicable detail...
BRCA2 mutant Talazoparib pancreatic cancer sensitive detail...
KRAS G12D AZD4785 pancreatic cancer sensitive detail...
Unknown unknown G-TPP + Obatoclax pancreatic cancer not applicable detail...
Unknown unknown G-TPP + Navitoclax pancreatic cancer not applicable detail...
BRAF mutant KO-947 pancreatic cancer predicted - sensitive detail...
NRAS mutant KO-947 pancreatic cancer predicted - sensitive detail...
Unknown unknown VX-970 + Radiotherapy pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Radiotherapy + VX-970 pancreatic cancer not applicable detail...
KRAS mutant KO-947 pancreatic cancer predicted - sensitive detail...
KRAS mutant Trametinib pancreatic cancer predicted - sensitive detail...
Unknown unknown Trametinib pancreatic cancer not applicable detail...
Unknown unknown Trabedersen pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Nimotuzumab pancreatic cancer not applicable detail...
MET wild-type Glesatinib pancreatic cancer decreased response detail...
Unknown unknown Galunisertib pancreatic cancer not applicable detail...
Unknown unknown NEO-102 pancreatic cancer not applicable detail...
Unknown unknown CHIR-124 + Gemcitabine pancreatic cancer not applicable detail...
BRCA2 loss NMS-P118 + Temozolomide pancreatic cancer sensitive detail...
STK11 mutant N/A pancreatic cancer not applicable detail...
CDKN2A mutant N/A pancreatic cancer not applicable detail...
MLH1 mutant N/A pancreatic cancer not applicable detail...
MSH6 mutant N/A pancreatic cancer not applicable detail...
BRCA1 mutant N/A pancreatic cancer not applicable detail...
BRCA2 mutant N/A pancreatic cancer not applicable detail...
Unknown unknown RX-3117 pancreatic cancer not applicable detail...
KRAS G12C Ulixertinib pancreatic cancer sensitive detail...
KRAS G12C RMC-4550 pancreatic cancer sensitive detail...
KRAS G12V RMC-4550 pancreatic cancer predicted - resistant detail...
KRAS G12D RMC-4550 pancreatic cancer predicted - resistant detail...
ERBB2 amp Pertuzumab + Trastuzumab pancreatic cancer predicted - sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab pancreatic cancer predicted - sensitive detail...
Unknown unknown Capecitabine + Gemcitabine + Tertomotide pancreatic cancer no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00871169 Phase II Irinotecan + Oxaliplatin + Cetuximab Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer Completed
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT01351103 Phase I LGK974 LGK974 + PDR001 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed
NCT01497392 Phase I Gemcitabine Dovitinib Capecitabine Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers Completed
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Recruiting
NCT01822756 Phase I Ruxolitinib An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors Terminated
NCT01888965 Phase II Dovitinib Maintenance Dovitinib for Colorectal and Pancreas Cancer Terminated
NCT01928394 Phase Ib/II Ipilimumab Nivolumab A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT02030067 Phase Ib/II RX-3117 Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies Active, not recruiting
NCT02048943 Phase I Dovitinib + Gemcitabine + Abraxane nab-paclitaxel Dovitinib Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer Withdrawn
NCT02154737 Phase I Erlotinib + Gemcitabine Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer Unknown status
NCT02237157 Phase I Gemcitabine A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Unknown status
NCT02305186 Phase Ib/II Pembrolizumab Capecitabine Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer Recruiting
NCT02341625 Phase Ib/II BMS-986148 BMS-986148 + Nivolumab A Study of BMS-986148 in Patients With Select Advanced Solid Tumors Active, not recruiting
NCT02451553 Phase I Afatinib Capecitabine Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Active, not recruiting
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Active, not recruiting
NCT02546531 Phase I Defactinib + Gemcitabine + Pembrolizumab Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer Recruiting
NCT02559674 Phase Ib/II ALT-803 + Gemcitabine + nab-paclitaxel ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel Active, not recruiting
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Active, not recruiting
NCT02581215 Phase II Ramucirumab FOLFIRINOX Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer Recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated
NCT02713529 Phase Ib/II AMG820 + Pembrolizumab Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Active, not recruiting
NCT02715531 Phase I Atezolizumab + Gemcitabine + nab-paclitaxel Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Atezolizumab + Bevacizumab + Capecitabine A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors Recruiting
NCT02760797 Phase I Emactuzumab + RO7009789 A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed
NCT02795156 Phase II Afatinib Regorafenib Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Recruiting
NCT02829723 Phase Ib/II BLZ945 BLZ945 + PDR001 Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Recruiting
NCT02897375 Phase I Cisplatin + Palbociclib Carboplatin + Palbociclib Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Recruiting
NCT02947165 Phase I NIS793 + PDR001 NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Active, not recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Recruiting
NCT02963831 Phase Ib/II ONCOS-102 + MEDI4736 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting
NCT02983578 Phase II AZD9150 + Durvalumab AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer Recruiting
NCT03018405 Phase I NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Recruiting
NCT03023722 Phase II Anetumab ravtansine Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer Recruiting
NCT03033225 Phase II Verteporfin EUS-guided PDT in Pancreatic Tumors Recruiting
NCT03040986 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations Suspended
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting
NCT03080974 Phase II Nivolumab Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma Recruiting
NCT03087591 Phase I APN401 APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Recruiting
NCT03098160 Phase I Evofosfamide + Ipilimumab Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Recruiting
NCT03136406 Phase Ib/II GI-4000 Leucovorin Avelumab nab-paclitaxel Bevacizumab Cyclophosphamide Capecitabine Oxaliplatin Fluorouracil ETBX-011 ALT-803 QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Active, not recruiting
NCT03161379 Phase II Cyclophosphamide + GVAX pancreatic cancer vaccine + Nivolumab Phase 2 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer Recruiting
NCT03184870 Phase Ib/II BMS-813160 + Fluorouracil + Irinotecan + Leucovorin BMS-813160 + Nivolumab BMS-813160 + Gemcitabine + nab-paclitaxel BMS-813160 A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03189914 Phase Ib/II RX-3117 RX-3117 in Combination With Abraxane in Subjects With Metastatic Pancreatic Cancer Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03207867 Phase II PBF-509 + PDR001 A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03257761 Phase I Durvalumab + Guadecitabine Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting
NCT03329248 Phase Ib/II mFOLFOX-6 ALT-803 + Avelumab + Bevacizumab + ETBX-011 + GI-4000 Capecitabine + Cyclophosphamide + nab-paclitaxel QUILT-3.060: Combination Immunotherapy With High-affinity Natural Killer (haNK) in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy. Active, not recruiting
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Recruiting
NCT03454035 Phase I Palbociclib + Ulixertinib Phase I Trial of Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors Recruiting
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting
NCT03485209 Phase II Tisotumab Vedotin Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Recruiting
NCT03599362 Phase II Cabiralizumab + Nivolumab Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer Recruiting
NCT03601923 Phase II Niraparib Niraparib in Patients With Pancreatic Cancer Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03784677 Phase I SOR-C13 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Not yet recruiting
NCT03785210 Phase II Nivolumab + Tadalafil + Vancomycin Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Not yet recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting